APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dotinurad Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dotinurad Tablets Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchDotinurad Tablets Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Dotinurad Tablets Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Dotinurad Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dotinurad Tablets Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Dotinurad Tablets Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Dotinurad Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dotinurad Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dotinurad Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dotinurad Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dotinurad Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dotinurad Tablets market include Fuji Yakuhin, Mochida Pharmaceutical, Ziska Pharmaceutical, Eisai and General Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dotinurad Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dotinurad Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dotinurad Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dotinurad Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Dotinurad Tablets Segment by Company

Fuji Yakuhin

Mochida Pharmaceutical

Ziska Pharmaceutical

Eisai

General Pharmaceuticals

Dotinurad Tablets Segment by Type

0.5mg per Tablet

1.0mg per Tablet

2.0mg per Tablet

Dotinurad Tablets Segment by Application

Gout

Hyperuricaemia

Other

Dotinurad Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dotinurad Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dotinurad Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dotinurad Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Dotinurad Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dotinurad Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dotinurad Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dotinurad Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dotinurad Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dotinurad Tablets industry.

Chapter 3: Detailed analysis of Dotinurad Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dotinurad Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dotinurad Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dotinurad Tablets Industry Trends Table 2. Dotinurad Tablets Industry Drivers Table 3. Dotinurad Tablets Industry Opportunities and Challenges Table 4. Dotinurad Tablets Industry Restraints Table 5. Global Dotinurad Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dotinurad Tablets Revenue Share by Company (2021-2026) Table 7. Global Dotinurad Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dotinurad Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Dotinurad Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dotinurad Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dotinurad Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Dotinurad Tablets Company, Product Type & Application Table 13. Global Dotinurad Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dotinurad Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 0.5mg per Tablet Table 18. Significant Companies of 1.0mg per Tablet Table 19. Significant Companies of 2.0mg per Tablet Table 20. Global Dotinurad Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Dotinurad Tablets Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Dotinurad Tablets Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Dotinurad Tablets Sales Volume Share by Type (2021-2026) Table 24. Global Dotinurad Tablets Sales Volume Share by Type (2027-2032) Table 25. Global Dotinurad Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Dotinurad Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Dotinurad Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Dotinurad Tablets Sales Value Share by Type (2021-2026) Table 29. Global Dotinurad Tablets Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Gout Table 31. Significant Companies of Hyperuricaemia Table 32. Significant Companies of Other Table 33. Global Dotinurad Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Dotinurad Tablets Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Dotinurad Tablets Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Dotinurad Tablets Sales Volume Share by Application (2021-2026) Table 37. Global Dotinurad Tablets Sales Volume Share by Application (2027-2032) Table 38. Global Dotinurad Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Dotinurad Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Dotinurad Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Dotinurad Tablets Sales Value Share by Application (2021-2026) Table 42. Global Dotinurad Tablets Sales Value Share by Application (2027-2032) Table 43. Global Dotinurad Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Dotinurad Tablets Sales by Region (2021-2026) & (K Units) Table 45. Global Dotinurad Tablets Sales Market Share by Region (2021-2026) Table 46. Global Dotinurad Tablets Sales by Region (2027-2032) & (K Units) Table 47. Global Dotinurad Tablets Sales Market Share by Region (2027-2032) Table 48. Global Dotinurad Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Dotinurad Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Dotinurad Tablets Sales Value Share by Region (2021-2026) Table 51. Global Dotinurad Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Dotinurad Tablets Sales Value Share by Region (2027-2032) Table 53. Global Dotinurad Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Dotinurad Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Dotinurad Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Dotinurad Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Dotinurad Tablets Sales by Country (2021-2026) & (K Units) Table 58. Global Dotinurad Tablets Sales Market Share by Country (2021-2026) Table 59. Global Dotinurad Tablets Sales by Country (2027-2032) & (K Units) Table 60. Global Dotinurad Tablets Sales Market Share by Country (2027-2032) Table 61. Global Dotinurad Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Dotinurad Tablets Sales Value Market Share by Country (2021-2026) Table 63. Global Dotinurad Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Dotinurad Tablets Sales Value Market Share by Country (2027-2032) Table 65. Fuji Yakuhin Company Information Table 66. Fuji Yakuhin Business Overview Table 67. Fuji Yakuhin Dotinurad Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Fuji Yakuhin Dotinurad Tablets Product Portfolio Table 69. Fuji Yakuhin Recent Development Table 70. Mochida Pharmaceutical Company Information Table 71. Mochida Pharmaceutical Business Overview Table 72. Mochida Pharmaceutical Dotinurad Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Mochida Pharmaceutical Dotinurad Tablets Product Portfolio Table 74. Mochida Pharmaceutical Recent Development Table 75. Ziska Pharmaceutical Company Information Table 76. Ziska Pharmaceutical Business Overview Table 77. Ziska Pharmaceutical Dotinurad Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ziska Pharmaceutical Dotinurad Tablets Product Portfolio Table 79. Ziska Pharmaceutical Recent Development Table 80. Eisai Company Information Table 81. Eisai Business Overview Table 82. Eisai Dotinurad Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eisai Dotinurad Tablets Product Portfolio Table 84. Eisai Recent Development Table 85. General Pharmaceuticals Company Information Table 86. General Pharmaceuticals Business Overview Table 87. General Pharmaceuticals Dotinurad Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. General Pharmaceuticals Dotinurad Tablets Product Portfolio Table 89. General Pharmaceuticals Recent Development Table 90. Key Raw Materials Table 91. Raw Materials Key Suppliers Table 92. Dotinurad Tablets Distributors List Table 93. Dotinurad Tablets Customers List Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Dotinurad Tablets Product Image Figure 2. Global Dotinurad Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dotinurad Tablets Sales (2021-2032) & (K Units) Figure 5. Global Dotinurad Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dotinurad Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 0.5mg per Tablet Image Figure 10. 1.0mg per Tablet Image Figure 11. 2.0mg per Tablet Image Figure 12. Global Dotinurad Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Dotinurad Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Dotinurad Tablets Sales Volume Share by Type (2021-2032) Figure 15. Global Dotinurad Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Dotinurad Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Dotinurad Tablets Sales Value Share by Type (2021-2032) Figure 18. Gout Image Figure 19. Hyperuricaemia Image Figure 20. Other Image Figure 21. Global Dotinurad Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Dotinurad Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Dotinurad Tablets Sales Volume Share by Application (2021-2032) Figure 24. Global Dotinurad Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Dotinurad Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Dotinurad Tablets Sales Value Share by Application (2021-2032) Figure 27. Global Dotinurad Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Dotinurad Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Dotinurad Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Dotinurad Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 32. North America Dotinurad Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Dotinurad Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Dotinurad Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 38. South America Dotinurad Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Dotinurad Tablets Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Dotinurad Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Dotinurad Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Dotinurad Tablets Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Dotinurad Tablets Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 0.5mg per Tablet
  • 1.0mg per Tablet
  • 2.0mg per Tablet
Applications
  • Gout
  • Hyperuricaemia
  • Other
Companies covered
  • Fuji Yakuhin
  • Mochida Pharmaceutical
  • Ziska Pharmaceutical
  • Eisai
  • General Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dotinurad Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Dotinurad Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Dotinurad Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dotinurad Tablets Market Dynamics
  1. 2.1 Dotinurad Tablets Industry Trends
  2. 2.2 Dotinurad Tablets Industry Drivers
  3. 2.3 Dotinurad Tablets Industry Opportunities and Challenges
  4. 2.4 Dotinurad Tablets Industry Restraints
3 Dotinurad Tablets Market by Company
  1. 3.1 Global Dotinurad Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Dotinurad Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Dotinurad Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Dotinurad Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Dotinurad Tablets Company Ranking (2024-2026)
  6. 3.6 Global Dotinurad Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Dotinurad Tablets Company Product Type and Application
  8. 3.8 Global Dotinurad Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dotinurad Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dotinurad Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dotinurad Tablets Market by Type
  1. 4.1 Dotinurad Tablets Type Introduction
  2. 4.1.1 0.5mg per Tablet
  3. 4.1.2 1.0mg per Tablet
  4. 4.1.3 2.0mg per Tablet
  5. 4.2 Global Dotinurad Tablets Sales Volume by Type
  6. 4.2.1 Global Dotinurad Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Dotinurad Tablets Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Dotinurad Tablets Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Dotinurad Tablets Sales Value by Type
  10. 4.3.1 Global Dotinurad Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Dotinurad Tablets Sales Value by Type (2021-2032)
  12. 4.3.3 Global Dotinurad Tablets Sales Value Share by Type (2021-2032)
5 Dotinurad Tablets Market by Application
  1. 5.1 Dotinurad Tablets Application Introduction
  2. 5.1.1 Gout
  3. 5.1.2 Hyperuricaemia
  4. 5.1.3 Other
  5. 5.2 Global Dotinurad Tablets Sales Volume by Application
  6. 5.2.1 Global Dotinurad Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dotinurad Tablets Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Dotinurad Tablets Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Dotinurad Tablets Sales Value by Application
  10. 5.3.1 Global Dotinurad Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dotinurad Tablets Sales Value by Application (2021-2032)
  12. 5.3.3 Global Dotinurad Tablets Sales Value Share by Application (2021-2032)
6 Dotinurad Tablets Regional Sales and Value Analysis
  1. 6.1 Global Dotinurad Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dotinurad Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Dotinurad Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Dotinurad Tablets Sales by Region (2027-2032)
  5. 6.3 Global Dotinurad Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dotinurad Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dotinurad Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dotinurad Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Dotinurad Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dotinurad Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Dotinurad Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dotinurad Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Dotinurad Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dotinurad Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dotinurad Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dotinurad Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Dotinurad Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dotinurad Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dotinurad Tablets Sales Value Share by Country, 2025 VS 2032
7 Dotinurad Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Dotinurad Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dotinurad Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dotinurad Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Dotinurad Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Dotinurad Tablets Sales by Country (2027-2032)
  6. 7.4 Global Dotinurad Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dotinurad Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dotinurad Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dotinurad Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dotinurad Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dotinurad Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Fuji Yakuhin
  2. 8.1.1 Fuji Yakuhin Company Information
  3. 8.1.2 Fuji Yakuhin Business Overview
  4. 8.1.3 Fuji Yakuhin Dotinurad Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Fuji Yakuhin Dotinurad Tablets Product Portfolio
  6. 8.1.5 Fuji Yakuhin Recent Developments
  7. 8.2 Mochida Pharmaceutical
  8. 8.2.1 Mochida Pharmaceutical Company Information
  9. 8.2.2 Mochida Pharmaceutical Business Overview
  10. 8.2.3 Mochida Pharmaceutical Dotinurad Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mochida Pharmaceutical Dotinurad Tablets Product Portfolio
  12. 8.2.5 Mochida Pharmaceutical Recent Developments
  13. 8.3 Ziska Pharmaceutical
  14. 8.3.1 Ziska Pharmaceutical Company Information
  15. 8.3.2 Ziska Pharmaceutical Business Overview
  16. 8.3.3 Ziska Pharmaceutical Dotinurad Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ziska Pharmaceutical Dotinurad Tablets Product Portfolio
  18. 8.3.5 Ziska Pharmaceutical Recent Developments
  19. 8.4 Eisai
  20. 8.4.1 Eisai Company Information
  21. 8.4.2 Eisai Business Overview
  22. 8.4.3 Eisai Dotinurad Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eisai Dotinurad Tablets Product Portfolio
  24. 8.4.5 Eisai Recent Developments
  25. 8.5 General Pharmaceuticals
  26. 8.5.1 General Pharmaceuticals Company Information
  27. 8.5.2 General Pharmaceuticals Business Overview
  28. 8.5.3 General Pharmaceuticals Dotinurad Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 General Pharmaceuticals Dotinurad Tablets Product Portfolio
  30. 8.5.5 General Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dotinurad Tablets Value Chain Analysis
  2. 9.1.1 Dotinurad Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dotinurad Tablets Sales Mode & Process
  6. 9.2 Dotinurad Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dotinurad Tablets Distributors
  9. 9.2.3 Dotinurad Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst